Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

被引:1085
|
作者
Takemoto, M
Liao, JK
机构
[1] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
关键词
endothelium; vascular smooth muscle; platelets; atherosclerosis; inflammation;
D O I
10.1161/hq1101.098486
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The 3-hydroxy-3-methylglutaryl coenzyme. A reductase inhibitors or statins are potent inhibitors of cholesterol biosynthesis. Several large clinical trials have demonstrated the beneficial effects of statins in the primary and secondary prevention of coronary heart disease. However, the overall clinical benefits observed with statin therapy appear to be greater than what might be expected from changes in lipid profile alone, suggesting that the beneficial effects of statins may extend beyond their effects on serum cholesterol levels. Indeed, recent experimental and clinical evidence indicates that some of the cholesterol-independent or "pleiotropic" effects of statins involve improving or restoring endothelial function, enhancing the stability of atherosclerotic plaques, and decreasing oxidative stress and vascular inflammation. Many of these pleiotropic effects of statins are mediated by their ability to block the synthesis of important isoprenoid intermediates, which serve as lipid attachments for a variety of intracellular signaling molecules. In particular, the inhibition of small GTP-binding proteins, Rho, Ras, and Rac, whose proper membrane localization and function are dependent on isoprenylation, may play an important role in mediating the direct cellular effects of statins on the vascular wall.
引用
收藏
页码:1712 / 1719
页数:8
相关论文
共 50 条
  • [21] The role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in modern rheumatology
    Kotyla, Przemyslaw
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2010, 2 (05) : 257 - 269
  • [23] SOLUBILIZATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE
    ACKERMAN, ME
    SCALLEN, TJ
    CIRCULATION, 1972, 46 (04) : 255 - &
  • [24] PATHOGENESIS OF ATHEROSCLEROSIS AND THE ROLE OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A REDUCTASE INHIBITORS
    CORSINI, A
    RAITERI, M
    SOMA, MR
    BERNINI, F
    FUMAGALLI, R
    PAOLETTI, R
    AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (02): : A21 - A28
  • [25] INHIBITION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE BY CITRININ
    NESS, GC
    MOFFLER, MH
    FEDERATION PROCEEDINGS, 1978, 37 (06) : 1580 - 1580
  • [26] USE OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE INHIBITORS IN VARIOUS FORMS OF DYSLIPIDEMIA
    GRUNDY, SM
    VEGA, GL
    GARG, A
    AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (08): : B31 - B38
  • [27] 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors Unmask Cryptic Regulatory Mechanisms
    Lopez, D.
    Chambers, C. M.
    Ness, G. C.
    Archives of Biochemistry and Biophysics, 343 (01):
  • [28] Varicose Remodeling of Veins Is Suppressed by 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
    Eschrich, Johannes
    Meyer, Ralph
    Kuk, Hanna
    Wagner, Andreas H.
    Noppeney, Thomas
    Debus, Sebastian
    Hecker, Markus
    Korff, Thomas
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (02):
  • [30] 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion
    Huff, MW
    Burnett, JR
    CURRENT OPINION IN LIPIDOLOGY, 1997, 8 (03) : 138 - 145